A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors

被引:32
|
作者
Lavigne, Jill E. [1 ]
Heckler, Charles [2 ]
Mathews, Jennifer L. [1 ]
Palesh, Oxana [3 ]
Kirshner, Jeffrey J. [4 ]
Lord, Raymond [4 ]
Jacobs, Andrew [4 ]
Amos, Eric [1 ]
Morrow, Gary R. [2 ]
Mustian, Karen [2 ]
机构
[1] St John Fisher Coll, Wegmans Sch Pharm, Rochester, NY 14618 USA
[2] Univ Rochester, Med Ctr, Dept Radiat Oncol, James P Wilmot Canc Ctr, Rochester, NY 14642 USA
[3] Stanford Univ, Sch Med, Dept Psychiat, Palo Alto, CA 94304 USA
[4] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Community Clin Oncol Base, Rochester, NY 14642 USA
关键词
Gabapentin; Neurontin; Anti-epileptics; Breast; Cancer; Anxiety; Randomized controlled trial; Cancer survivorship; PRIMARY-CARE; FOLLOW-UP; PAIN; EFFICACY; MANAGEMENT; DISORDER; BENZODIAZEPINES; MULTICENTER; PREGABALIN; SURGERY;
D O I
10.1007/s10549-012-2251-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 50 条
  • [1] A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors
    Jill E. Lavigne
    Charles Heckler
    Jennifer L. Mathews
    Oxana Palesh
    Jeffrey J. Kirshner
    Raymond Lord
    Andrew Jacobs
    Eric Amos
    Gary R. Morrow
    Karen Mustian
    Breast Cancer Research and Treatment, 2012, 136 : 479 - 486
  • [2] A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors
    Thompson, EA
    Oxon, BA
    Montgomery, A
    Douglas, D
    Reilly, D
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2005, 11 (01) : 13 - 20
  • [3] Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial
    Mao, Jun J.
    Bowman, Marjorie A.
    Xie, Sharon X.
    Bruner, Deborah
    DeMichele, Angela
    Farrar, John T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) : 3615 - +
  • [4] Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer:a multicenter, randomized,double-blinded,placebo-controlled,phase Ⅱclinical trial
    RuiHua Xu
    Lin Shen
    KeMing Wang
    Gang Wu
    ChunMei Shi
    KeFeng Ding
    LiZhu Lin
    JinWan Wang
    JianPing Xiong
    ChangPing Wu
    Jin Li
    YunPeng Liu
    Dong Wang
    Yi Ba
    JuePing Feng
    YuXian Bai
    JingWang Bi
    LiWen Ma
    Jian Lei
    Qing Yang
    Hao Yu
    Chinese Journal of Cancer, 2017, 36 (12) : 677 - 685
  • [5] A double-blinded randomized controlled trial of coblation versus conventional dissection tonsillectomy on postoperative symptoms
    Rachmanidou, A
    Robb, PJ
    Timms, M
    CLINICAL OTOLARYNGOLOGY, 2005, 30 (05) : 477 - 478
  • [6] EFFICACY OF GABAPENTIN IN THE TREATMENT OF ALCOHOL DEPENDENCE: A DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Kalayasiri, R.
    Chompookham, P.
    Rukngan, W.
    Nilaban, S.
    Suwanmajo, S.
    Yoosom, P.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 42 : 13A - 13A
  • [7] Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
    Xu, Rui-Hua
    Shen, Lin
    Wang, Ke-Ming
    Wu, Gang
    Shi, Chun-Mei
    Ding, Ke-Feng
    Lin, Li-Zhu
    Wang, Jin-Wan
    Xiong, Jian-Ping
    Wu, Chang-Ping
    Li, Jin
    Liu, Yun-Peng
    Wang, Dong
    Ba, Yi
    Feng, Jue-Ping
    Bai, Yu-Xian
    Bi, Jing-Wang
    Ma, Li-Wen
    Lei, Jian
    Yang, Qing
    Yu, Hao
    CHINESE JOURNAL OF CANCER, 2017, 36
  • [8] Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: A prospective, randomized, double-blinded clinical trial
    Heyworth, Benton E.
    Lee, Jonathan H.
    Kim, Paul D.
    Lipton, Carter B.
    Strauch, Robert J.
    Rosenwasser, Melvin P.
    JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 2008, 33A (01): : 40 - 48
  • [9] A double-blinded randomized controlled trial of coblation versus conventional dissection tonsillectomy on postoperative symptoms -: Response
    Philpott, C
    Wild, D
    Mehta, D
    Daniel, M
    Banerjee, A
    CLINICAL OTOLARYNGOLOGY, 2005, 30 (05): : 478 - 479
  • [10] Administration of Preoperative Gabapentin to Patients Undergoing Laparoscopy: A Double-Blinded, Placebo-Controlled Randomized Trial
    Benton, Andrea
    Harkins, Gerald
    Stetter, Christina
    Kunselman, Allen
    Deimling, Timothy
    Riley, Kristin
    JOURNAL OF GYNECOLOGIC SURGERY, 2020, 36 (04) : 173 - 178